A Phase Ib, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Anti-tumour Activity of AZD1775 Monotherapy in Patients With Advanced Solid Tumours

Trial ID # NCT02482311
Phase Ib
Drug Class Cell Cycle Inhibitors: Wee1
Drug Name Adavosertib
Alternate Drug Names WEE1 inhibitor AZD1775, MK1775, AZD1775
Drugs in Trial Adavosertib
Eligible Participant

Advanced solid tumors (with expansions in BRCA1/2 MUT ovarian cancer after PARPi-failure and BRCA WT ovarian cancer)

Patients Enrolled

80 (30 BRCA1/2 MUT ovarian cancer after PARPi-failure, median 6 prior therapies; 16 BRCA WT ovarian cancer, median 7 prior therapies)

Therapy Setting


Study Design

Open-Label, Non-randomized


ORR, DCR, PFS, evaluated per RECIST




Adavosertib (175 mg PO bid) on days 1–3 and 8–10 per 21-day cycle

BRCA MUT after PARPi failure (n=30):
ORR: 3.3% (1PR); DCR: 77% (1PR, 22SD) - 1 patient with SD had CCNE1 AMP  (no other patients with CCNE1 AMP)
PFS: 3.9 months

BRCA WT (n=16):
ORR: 6.3% (1PR); DCR: 69% (1PR, 10SD) - patient with PR had CCNE1 AMP (no other patients with CCNE1 AMP)
PFS: 4.5 months

Clinically Significant Adverse Events

Serious AE: 1 death
Grade 3-4AE:


Adavosertib was well tolerated and showed preliminary antitumor activity. No clear correlation between genomic profile and clinical response was observed


Bauer TM et al. A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors. Target Oncol (2023) 18(4):517-530

Contact Us
Contact Us

We are here to help! Send us a message below or give us a call at (858) 657-0282.